No headlines found.
Globe Newswire (Wed, 5-Mar 5:52 PM ET)
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences
Yolowire (Wed, 5-Mar 3:32 PM ET)
Agios to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 4-Mar 7:00 AM ET)
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025
Globe Newswire (Thu, 20-Feb 7:00 AM ET)
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 13-Feb 6:31 AM ET)
Globe Newswire (Thu, 13-Feb 6:30 AM ET)
Globe Newswire (Thu, 6-Feb 7:00 AM ET)
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
Globe Newswire (Mon, 13-Jan 7:00 AM ET)
Globe Newswire (Wed, 8-Jan 7:00 AM ET)
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Globe Newswire (Fri, 3-Jan 7:00 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of March 5, 2025, AGIO stock price climbed to $33.95 with 468,674 million shares trading.
AGIO has a beta of 1.87, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.11 to the broad based SPY ETF.
AGIO has a market cap of $1.95 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $11 million in Revenue and -$1.94 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.31.
In the last 3 years, AGIO traded as high as $62.58 and as low as $16.75.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.
AGIO has underperformed the market in the last year with a return of +5.5%, while the SPY ETF gained +15.2%. In the last 3 month period, AGIO fell short of the market, returning -42.9%, while SPY returned -3.7%. However, in the most recent 2 weeks AGIO has outperformed the stock market by returning +1.0%, while SPY returned -4.6%.
AGIO support price is $32.37 and resistance is $34.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.